Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications

Bibliography

• Scharf M. Eszopiclone for the treatment of insomnia. Expert Opin Pharmacother 2006;7:345-56
   PubMed Web of Science ®Google Scholar
• Monti JM, Pandi-Perumal SR. Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat 2007;3:441-53
   PubMedGoogle Scholar
• Melton ST, Wood JM, Kirkwood CK. Eszopiclone for insomnia. Ann Pharmacother 2005;39:1659-66
   PubMed Web of Science ®Google Scholar
• Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 2006;28:491-516
   PubMed Web of Science ®Google Scholar
• McCrae CS, Ross A, Stripling A, Eszopiclone for late-life insomnia. Clin Interv Aging 2007;2:313-26
   PubMed Web of Science ®Google Scholar
• Morin AK, Willett K. The role of eszopiclone in the treatment of insomnia. Adv Ther 2009;26:500-18
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug prescribing in the United States: extent, costs, and expenditures. J Clin Psychopharmacol 2011;31:1-3
   PubMed Web of Science ®Google Scholar
• Drug Topics. Available from: www.drugtopics.com [Accessed 2 August 2012]
   Google Scholar
• Miller CP, Ullrich JW. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States. Chirality 2008;20:762-70
   PubMed Web of Science ®Google Scholar
• Agranat I, Wainschtein SR. The strategy of enantiomer patents of drugs. Drug Discov Today 2010;15:163-70
   PubMed Web of Science ®Google Scholar
• Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002;1:753-68
   PubMed Web of Science ®Google Scholar
• Mansfield P, Henry D, Tonkin A. Single-enantiomer drugs: elegant science, disappointing effects. Clin Pharmacokinet 2004;43:287-90
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Feetam CL. What one hand giveth the other taketh away: some unpredicted effects of enatiomers in psychopharmacology. J Psychopharmacol 2012;24:1137-41
   Web of Science ®Google Scholar
• Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 2009;24:1601-12
   PubMed Web of Science ®Google Scholar
• Sanchez C, Bogeso KP, Ebert B, Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004;174:163-76
   PubMed Web of Science ®Google Scholar
• Blaschke G, Hempel G, Muller WE. Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality 1993;5:419-21
   PubMed Web of Science ®Google Scholar
• Carlson JN, Haskew R, Wacker J, Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur J Pharmacol 2001;415:181-9
   PubMed Web of Science ®Google Scholar
• Hopkins SC, Brian Nofsinger J, Allen MS, In vivo saturation binding of GABA-A receptor ligands to estimate receptor occupancy using liquid chromatography/tandem mass spectrometry. Biopharm Drug Dispos 2009;30:9-20
   PubMed Web of Science ®Google Scholar
• Becquemont L, Mouajjah S, Escaffre O, Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 1999;27:1068-73
   PubMed Web of Science ®Google Scholar
• fda.gov/drugsatfda_docs/NDA/2004/021476_lunesta.cfm
   Google Scholar
• Tornio A, Neuvonen PJ, Backman JT. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol 2006;62:645-51
   PubMed Web of Science ®Google Scholar
• Mistri HN, Jangid AG, Pudage A, HPLC-ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008;864:137-48
   PubMed Web of Science ®Google Scholar
• Aranko K, Luurila H, Backman JT, The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. Br J Clin Pharmacol 1994;38:363-7
   PubMed Web of Science ®Google Scholar
• Jalava K-M, Olkkola KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Eur J Clin Pharmacol 1996;51:331-4
   PubMed Web of Science ®Google Scholar
• Villikka K, Kivistö KT, Lamberg TS, Concentraions and effects of zopiclone are greatly reduced by rifampicin. Br J Clin Pharmacol 1997;43:471-4
   PubMed Web of Science ®Google Scholar
• Yin H, Racha J, Li SY, Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. Xenobiotica 2000;30:141-54
   PubMed Web of Science ®Google Scholar
• Khojasteh SC, Prabhu S, Kenny JR, Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 2011;36:1-16
   PubMed Web of Science ®Google Scholar
• Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23:154-8
   PubMed Web of Science ®Google Scholar
• Fernandez C, Maradeix V, Gimenez F, Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 1993;21:1125-8
   PubMed Web of Science ®Google Scholar
• Fernandez C, Martin C, Gimenez F, Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet 1995;29:431-41
   PubMed Web of Science ®Google Scholar
• Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004;43:227-38
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Legangneux E, Harmatz JS, Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006;46:1469-80
   PubMed Web of Science ®Google Scholar
• Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, von Moltke LL, Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 2004;76:467-79
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Shapiro L, Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-8
   PubMed Web of Science ®Google Scholar
• Gaillot J, Le Roux Y, Houghton GW, Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 1987;10(Suppl 1):7-21
   PubMed Web of Science ®Google Scholar
• Parker G, Roberts CJ. Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease. Br J Clin Pharmacol 1983;16:259-65
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance. Clin Pharmacokinet 2000;38:111-80
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. Sleep and geriatric psychopharmacology. In: Pandi-Perumal SR, Verster JC, Monti JM, Lader MH, Langer SZ, editors. Sleep disorders: diagnosis and therapeutics. Informa Healthcare; London: 2008. p. 163-73
   Google Scholar
• Greenblatt DJ. Pharmacokinetic determinants of the clinical effects of benzodiazepine agonist hypnotics. In: Monti JM, Pandi-Perumal S, Möhler H, editors. GABA, Sleep. Springer; Basel: 2010. p. 95-118
   Google Scholar
• Greenblatt DJ, Roth T. Zolpidem for insomnia. Expert Opin Pharmacother 2012;13(6):879-93
   PubMed Web of Science ®Google Scholar
• Zammit GK, McNabb LJ, Caron J, Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91
   PubMed Web of Science ®Google Scholar
• O'Hanlon JF. Zopiclone's residual effects on psychomotor and information processing skills involved in complex tasks such as car driving: a critical review. Eur Psychiatry 1995;10:137s-43s
   PubMed Web of Science ®Google Scholar
• Mets MA, Volkerts ER, Olivier B, Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev 2010;14:259-67
   PubMed Web of Science ®Google Scholar
• Allain H, Bentue-Ferrer D, Tarral A, Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol 2003;59:179-88
   PubMed Web of Science ®Google Scholar
• Paul MA, Gray G, Kenny G, Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med 2003;74:1263-70
   PubMed Web of Science ®Google Scholar
• Allain H, Patat A, Lieury A, Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur Psychiatry 1995;10(Suppl 3):129s-35s
   Google Scholar
• Gustavsen I, Hjelmeland K, Bernard JP, Psychomotor performance after intake of zopiclone compared with intake of ethanol: a randomized, controlled, double-blinded trial. J Clin Psychopharmacol 2011;31:481-8
   PubMed Web of Science ®Google Scholar
• Roth T, Soubrane C, Titeux L, Walsh JK. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397-406
   PubMed Web of Science ®Google Scholar
• Verster JC, Veldhuijzen DS, Volkerts ER. Residual effects of sleep medication on driving ability. Sleep Med Rev 2004;8:309-25
   PubMed Web of Science ®Google Scholar
• Verster JC, Veldhuijzen DS, Patat A, Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf 2006;1:63-71
   PubMedGoogle Scholar
• Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18:297-328
   PubMed Web of Science ®Google Scholar
• Verster JC, Roth T. Gender differences in highway driving performance after administration of sleep medication: a review of the literature. Traffic Inj Prev 2012;13:286-92
   PubMed Web of Science ®Google Scholar
• Vermeeren A, Riedel WJ, van Boxtel MP, Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002;25:224-31
   PubMed Web of Science ®Google Scholar
• Staner L, Ertle S, Boeijinga P, Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berl) 2005;181:790-8
   PubMed Web of Science ®Google Scholar
• Bocca ML, Le Doze F, Etard O, Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology (Berl) 1999;143:373-9
   PubMed Web of Science ®Google Scholar
• Bocca ML, Marie S, Lelong-Boulouard V, Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects. Psychopharmacology (Berl) 2011;214:699-706
   PubMed Web of Science ®Google Scholar
• Mets MA, de Vries JM, de Senerpont Domis LM, Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep 2011;34:1327-34
   PubMed Web of Science ®Google Scholar
• Leufkens TR, Vermeeren A. Highway driving in the elderly the morning after bedtime use of hypnotics: a comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo. J Clin Psychopharmacol 2009;29:432-8
   PubMed Web of Science ®Google Scholar
• Leufkens TR, Lund JS, Vermeeren A. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 2009;18:387-96
   PubMed Web of Science ®Google Scholar
• Verster JC, Spence DW, Shahid A, Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability. Curr Drug Saf 2011;6:209-18
   PubMedGoogle Scholar
• Ramaekers JG, Conen S, de Kam PJ, Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology (Berl) 2011;215:321-32
   PubMed Web of Science ®Google Scholar
• Boyle J, Trick L, Johnsen S, Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol 2008;23:385-97
   PubMed Web of Science ®Google Scholar
• Goa KL, Heel RC. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986;32:48-65
   PubMed Web of Science ®Google Scholar
• Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf 2009;32:735-48
   PubMed Web of Science ®Google Scholar
• Nilsson GH, Kugelberg FC, Kronstrand R, Stability tests of zopiclone in whole blood. Forensic Sci Int 2010;200:130-5
   PubMed Web of Science ®Google Scholar
• Sha Y, Zhang L, Du GJ, Synthesis of RP 48497, an impurity of eszopiclone. Molecules 2008;13:1817-21
   PubMed Web of Science ®Google Scholar
• Erman MK, Zammit G, Rubens R, A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med 2008;4:229-34
   PubMed Web of Science ®Google Scholar
• Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003;17:513-32
   PubMed Web of Science ®Google Scholar
• Boyle J, Groeger JA, Paska W, A method to assess the dissipation of residual hypnotics: eszopiclone versus zopiclone. J Clin Psychopharmacol 2012;32:704-9
   PubMed Web of Science ®Google Scholar
• Scharf M, Erman M, Rosenberg R, A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005;28:720-7
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Caron J, Roth T, An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med 2005;6:15-22
   PubMed Web of Science ®Google Scholar
• Soares CN, Joffe H, Rubens R, Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006;108:1402-10
   PubMed Web of Science ®Google Scholar
• Fava M, McCall WV, Krystal A, Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006;59:1052-60
   PubMed Web of Science ®Google Scholar
• McCall WV, Erman M, Krystal AD, A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22:1633-42
   PubMed Web of Science ®Google Scholar
• Walsh JK, Krystal AD, Amato DA, Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007;30:959-68
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Roach JM, Scharf M, A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Med 2007;8:464-70
   PubMed Web of Science ®Google Scholar
• Pollack M, Kinrys G, Krystal A, Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008;65:551-62
   PubMed Web of Science ®Google Scholar
• Lettieri CJ, Quast TN, Eliasson AH, Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial. Sleep 2008;31:1310-16
   PubMed Web of Science ®Google Scholar
• Roth T, Price JM, Amato DA, The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. J Clin Psychiatry (Primary Care Companion) 2009;11:292-301
   PubMedGoogle Scholar
• Ancoli-Israel S, Krystal AD, McCall WV, A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010;33:225-34
   PubMed Web of Science ®Google Scholar
• Menza M, Dobkin RD, Marin H, Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord 2010;25:1708-14
   PubMed Web of Science ®Google Scholar
• Joffe H, Petrillo L, Viguera A, Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol 2010;202:171 e171-171 e111
   PubMed Web of Science ®Google Scholar
• Pollack MH, Hoge EA, Worthington JJ, Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:892-7
   PubMed Web of Science ®Google Scholar
• Krystal AD, Walsh JK, Laska E, Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-9
   PubMed Web of Science ®Google Scholar
• Costco Pharmacy Drug Information. Available from: www.costco.com/pharmacy/druginformation [Accessed 2 August 2012]
   Google Scholar